Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ONCT)

GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016

Business Wire April 27, 2016

GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results

Business Wire March 3, 2016

GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx SARMs on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Business Wire February 24, 2016

GTx, Inc. to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast

Business Wire February 18, 2016

GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Business Wire January 13, 2016

Equities on the Move - Research on GTX Inc, Juniper Pharmaceuticals, Catabasis Pharmaceuticals and Amber Road

Accesswire December 1, 2015

GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results

Business Wire October 29, 2015

GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call and Webcast

Business Wire October 15, 2015

GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence

Business Wire October 13, 2015

GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in Triple Negative Breast Cancer

Business Wire October 6, 2015

GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer

Business Wire September 29, 2015

GTx Provides Corporate Update and Reports Second Quarter 2015 Financial Results

Business Wire August 6, 2015

GTx, Inc. To Host Second Quarter 2015 Financial Results Conference Call and Webcast

Business Wire July 23, 2015

GTx Appoints Diane Young, M.D. as Vice President, Chief Medical Officer

Business Wire July 8, 2015

GTx Regains Compliance with NASDAQ Bid Price Requirement

Business Wire June 2, 2015

GTx Announces Webcast of Corporate Presentation at Jefferies 2015 Global Healthcare Conference

Business Wire May 26, 2015

GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2015

Business Wire May 12, 2015

GTx Provides Corporate Update and Reports First Quarter 2015 Financial Results

Business Wire May 8, 2015

GTx and the University of Tennessee Research Foundation Enter Into Exclusive License Agreement to Develop UTRF's SARD Drug Technology

Business Wire April 23, 2015

GTx Provides Corporate Update Regarding NASDAQ Stock Listing

Business Wire April 2, 2015